Kirsten Lyke, MD: Progress Toward Malaria Vaccine


Since 2000 there's been a 30% overall reduction in malaria, however, a vaccine is needed as another tool.

Kirsten Lyke, MD, Institute for Global Health, University of Maryland School of Medicine: We're in a pretty exciting time in that malaria has been reduced by about 47% in terms of mortality and about 30% overall reduction in malaria since the year 2000, and that's primarily because of a huge influx of money from places like The Global Fund, Roll Back Malaria but also distribution of bed nets, implementation of medications. But I think we won't ever eradicate malaria unless we also have a vaccine to use as another tool in the armamentarium.

Malaria is kind of the holy grail of vaccine development. And the effort's been going on for 50 years and it's very tricky because not only does malaria have several stages that it passes through but it also sequesters within the red blood cell and that's an immunologic sanctuary, it doesn't have the proteins that are needed for antigen recognition, so it's essentially protected within the red blood cell, and then the third prong of why it's so tricky is because it has a very sophisticated genetic makeup that makes it a chameleon so that it's able to really change the coding rapidly and frequently so that there's almost limitless permutations of its genetic code. And that's very, very difficult to try to develop a vaccine against.

Related Coverage:

DAAs Proves Capable for HCV-Infected Heart Transplant Patients

Ebola Vaccines Provide Year-Long Immune Response

Another Investigational Vaccine Fails to Reduce RSV Infections

Related Videos
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Signs and Symptoms of Connective Tissue Disease
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
© 2024 MJH Life Sciences

All rights reserved.